U.S. Markets close in 4 hrs 17 mins

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
39.978+0.058 (+0.145%)
As of 11:42AM EDT. Market open.
People also watch
AZNNVSSNYLLYBMY
Full screen
Previous Close39.920
Open39.940
Bid39.960 x 400
Ask39.970 x 1600
Day's Range39.940 - 40.110
52 Week Range37.200 - 44.540
Volume1,113,095
Avg. Volume2,712,184
Market Cap91.34B
Beta0.98
PE Ratio (TTM)39.74
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.99 (4.93%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
    Zacks2 hours ago

    Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?

    GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

  • Reuters8 hours ago

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments. Britain's biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair. Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca's long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

  • FDA OKs Glaxo's inhaler, first one to combine 3 medicines
    Associated Press19 hours ago

    FDA OKs Glaxo's inhaler, first one to combine 3 medicines

    TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.